Find Clinical Trial

Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer’s disease. A 24- week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study followed by a 24-week extension period


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationAlzheimer's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S038093

Active Substance CodeS038093
Protocol CodeCL2-38093-011
EudraCT Code2010-024626-37
ISRCTN CodeISRCTN89039808


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility